Answers are grounded in this paper and cite their sources.
Objective The mounting evidence suggests that the immune status participates in the advancement and metastasis of UCEC as an important element, yet there is currently a dearth of effective and readily detectable biomarkers to reflect this phenomenon. The present study aimed to investigate the expression level, clinical significance, biological function, and immunoinfiltration characteristics of LSM4 in UCEC through bioinformatics analysis. Additionally, cytological experiments were carried out to validate the biological effect of LSM4 and assess its feasibility as a satisfactory endpoint of therapy and prognostic indicator for the patients. Methods The correlation between LSM4 and 12 clinicopathologic variables was mined using a variety of statistical algorithms. The GO, KEGG, and GSEA enrichment situation were conducted using R software to identify differences and biological functions of different LSM4 gene level, while PPI analysis was realized by the STRING database. The ESTIMATE algorithm was utilized to estimate the TME scores. Furthermore, the role of CIBERSORT was to estimate 22 distinct types of immune infiltrating cells in the tumor immune microenvironment. Kaplan-Meier survival analysis was conducted on DIICs, while the correlation between DIICs and LSM4 expression were demonstrated. The TIMER 2.0 database was utilized to perform online analysis on the correlation between LSM4 and immunoinfiltration. The TISIDB database was utilized to retrieve the association between LSM4 and immune regulatory genes, TCGA molecular typing, immune typing as well as clinical variables. R-package pRRophetic was employed to access GDSC database for analyzing the influence of LSM4 on chemotherapy and targeted drug sensitivities, while GSCALite database was utilized to screen for small molecule drugs related to LSM4. Q-PCR and Western Blot analyses were employed to validate the differential expression of LSM4 in cancer tissues and cells compared to normal conduction. Additionally, CCK8, Transwell and wound healing experiments were performed to ascertain the impression of siLSM4 on biological functions of Ishikawa and KLE cells. Results In UCEC, the expression of LSM4 is upregulated, which is significantly associated with the deterioration of PFS as well as various adverse clinicopathological features. LSM4 is mainly involved in the regulation of circulating immune complex formation, humoral immunity, classical complement activation pathway, antigen binding. The high expression of LSM4 exhibited a negative correlation with immune score, stromal score, multiple immune cells, GZMA, and most immune cell markers, thereby attenuating the immune activity within the microenvironment. Both immune prediction models further substantiated the involvement of LSM4 in regulating immune infiltration among the patients. Additionally, the presence of high LSM4 expression leads to a reduction in efficacy of immune checkpoint inhibitors and changes sensitivity to certain chemotherapy and small molecule targeted therapies. The fifteen small molecule drugs related to LSM4 have been identified. The expression of LSM4 was found to be up-regulated in both UCEC tissues and cells, thereby promoting tumor proliferation and migration. Conclusion All in all, we concluded that high mRNA of LSM4 may lead to a poor prognosis for the patients by facilitating tumor immune evasion and treatment resistance. Therefore, LSM4 could attend as a prospective bookmark and prognostic indicator for targeted therapy in UCEC.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: